Thomas Decaens

13.2k citations
141 papers · 3.9k · 1 hit paper · h-index 31

Impact in

  • Hepatology top 0.2%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Liver physiology and pathology
    • Liver Disease and Transplantation

Papers in

    • Hepatocellular Carcinoma Treatment and Prognosis 76
    • Liver physiology and pathology 17
    • Hepatitis C virus research 12
    • Liver Disease Diagnosis and Treatment 38
    • Hepatitis B Virus Studies 17

Thomas Decaens

129 papers receiving 3.8k citations

Thomas Decaens's Hit Papers

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. 2024 · 75 citations
750+1Years since publication255075

Peers

Thomas Decaens
Comparison fields: 5 of 98
  • Hepatology 2.3k
  • Cancer Research 591
  • Epidemiology 1.3k
  • Oncology 720
  • Pathology and Forensic Medicine 437
Replace Arndt Vogel with:
Arndt Vogel Germany
Wen‐Ming Cong China
Max W. Sung United States
Su Pin Choo Singapore
Renumathy Dhanasekaran United States
M. Schwartz United States
Tohru Utsunomiya Japan
Aiwu Ruth He United States
Sandra Rebouissou France
Baogang Peng China
Thomas Decaens relative to Arndt Vogel Germany Arndt Vogel's profile →
Citations per field
00.5×1.5×
Arndt Vogel · 1×
Citations per year

Countries citing papers authored by Thomas Decaens

Since Specialization
Citations

This map shows the geographic impact of Thomas Decaens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Decaens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Decaens more than expected).

Fields of papers citing papers by Thomas Decaens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Decaens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Decaens. The network helps show where Thomas Decaens may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Decaens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Decaens Line = papers co-authored together Thomas Decaens links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 141 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2006385
2 2013261
3 2013245
4 2004238
5 2009217
6 2005162
7 2017153
8 2006126
9 2007124
10 201499
11 201981
12
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Hit paper breakdown →
202475
13 201865
14 201359
15 201753
16 201953
17 201852
18 201250
19 200648
20 202146

About Thomas Decaens

Thomas Decaens is a scholar working on Hepatology, Epidemiology, Oncology, Surgery and Molecular Biology, having authored 141 papers that have together received 3.9k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (76 papers), Liver Disease Diagnosis and Treatment (38 papers), Cancer Immunotherapy and Biomarkers (18 papers), Liver physiology and pathology (17 papers), Hepatitis B Virus Studies (17 papers), Cancer Mechanisms and Therapy (15 papers), Organ Transplantation Techniques and Outcomes (15 papers) and Hepatitis C virus research (12 papers). The work is most often cited by research in Hepatology (2.3k citations), Cancer Research (591 citations), Epidemiology (1.3k citations), Oncology (720 citations) and Pathology and Forensic Medicine (437 citations). Thomas Decaens has collaborated with scholars based in France, United States and South Korea. Frequent co-authors include Zuzana Macek Jílková, Christine Perret, Sabine Colnot, Cécile Godard, Christophe Duvoux, Alexis Laurent, Snorri S. Thorgeirsson, Jesper B. Andersen, Matthias S. Matter and Gaël S. Roth. Their work appears in journals such as Journal of Hepatology, Annals of Oncology, Cancers, Journal of Clinical Oncology and Liver International.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact